Home » Stocks » CMMB

Chemomab Therapeutics Ltd. (CMMB)

Stock Price: $17.23 USD -0.50 (-2.82%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $17.20 -0.03 (-0.17%) Jul 26, 7:58 PM
Market Cap 195.08M
Revenue (ttm) n/a
Net Income (ttm) -9.78M
Shares Out 11.00M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $17.23
Previous Close $17.73
Change ($) -0.50
Change (%) -2.82%
Day's Open 17.86
Day's Range 17.02 - 18.49
Day's Volume 360,345
52-Week Range 15.18 - 2,700.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TEL AVIV, Israel and SEATTLE, June 23, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeuti...

1 month ago - PRNewsWire

Chemomab Therapeutics LTD. (NASDAQ: CMMB) shares are trading higher Friday as retail traders continue to push stocks higher.

1 month ago - Benzinga

TEL AVIV, Israel, June 10, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibro...

1 month ago - PRNewsWire

TEL-AVIV, Israel, May 13, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosi...

2 months ago - PRNewsWire

TEL AVIV, Israel, May 12, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosi...

2 months ago - PRNewsWire

TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibr...

3 months ago - PRNewsWire

TEL-AVIV, Israel, March 29, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibr...

3 months ago - PRNewsWire

Anchiano s hareholders approve all resolutions at shareholder meeting

Other stocks mentioned: ANCN
4 months ago - GlobeNewsWire

Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.

Other stocks mentioned: IMVT, OPGN, ANCN
4 months ago - Benzinga

Anchiano Therapeutics (ANCN) stock is rocketing higher on Monday after a shareholder letter caught the interest of investors. The post ANCN Stock: Speculation Around Investor Letter Sends Anchiano Thera...

Other stocks mentioned: ANCN
4 months ago - InvestorPlace

ANCN stock is an early stage company engaged in clinical trials for rare liver, lung and skin diseases with no FDA-approved options now. The post ANCN Stock: 10 Things to Know as Anchiano Therapeutics R...

Other stocks mentioned: ANCN
5 months ago - InvestorPlace

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or ...

Other stocks mentioned: ANCN, CATM, CHNG, CPAH
5 months ago - PRNewsWire

NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Anchiano Therapeutics Ltd. (NASDAQ: ANCN) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger o...

Other stocks mentioned: ANCN
7 months ago - PRNewsWire

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Anchiano Therapeutics Ltd. ("Anchiano" ...

Other stocks mentioned: ANCN
7 months ago - PRNewsWire

Anchiano Therapeutics (ANCN) stock is soaring higher on Tuesday following news of a merger with Chemomab that will bring major changes. The post ANCN Stock: Why Anchiano Therapeutics Stock Is Blasting H...

Other stocks mentioned: ANCN
7 months ago - InvestorPlace

As of Dec. 10, the GuruFocus All-in-One Screener, a Premium feature, found that the following health care companies have low price-earnings ratios and are owned by gurus. While some of them are great va...

Other stocks mentioned: ANCN, HAPP, TMDI, YCBD, ZCMD
7 months ago - GuruFocus

Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Other stocks mentioned: ANCN
9 months ago - Zacks Investment Research

CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPa...

Other stocks mentioned: ANCN
1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s 202...

Other stocks mentioned: ANCN
1 year ago - GlobeNewsWire

About CMMB

Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Industry
Biotechnology
Founded
2004
Stock Exchange
NASDAQ
Ticker Symbol
CMMB
Full Company Profile

Financial Performance

Financial Statements